The use of magnetite nanoparticles for implant-assisted magnetic drug targeting in thrombolytic therapy

Biomaterials

Volumn 31, Issue 36, 2010, Pages 9499-9510

  Kempe, Henrik ^a   Kempe, Maria ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Enzyme immobilization; Implant assisted magnetic drug targeting; In vivo pig model; In stent thrombosis; Magnetic nanoparticles; Thrombolysis

Indexed keywords

IN-STENT THROMBOSIS; IN-VIVO; MAGNETIC DRUG TARGETING; MAGNETIC NANOPARTICLES; THROMBOLYSIS;

BIOCOMPATIBILITY; BLOOD VESSELS; CHLORINE COMPOUNDS; DISEASES; DRUG DELIVERY; ENZYME IMMOBILIZATION; ENZYMES; HYSTERESIS; HYSTERESIS LOOPS; MAGNETIC FIELD EFFECTS; MAGNETIC MATERIALS; MAGNETITE; NANOPARTICLES; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; PRECIPITATION (CHEMICAL); SATURATION MAGNETIZATION;

NANOMAGNETICS;

2,2,2 TRIFLUOROETHANESULFONYL CHLORIDE; ALTEPLASE; CHLORIDE; FERROMAGNETIC MATERIAL; FERROUS HYDROXIDE; IRON DERIVATIVE; MACROGOL; MAGNETIC NANOPARTICLE; MAGNETITE; SUCCINIMIDE DERIVATIVE; TETRAETHOXYSILANE; TISSUE PLASMINOGEN ACTIVATOR; TRIETHYLENE GLYCOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCOMPATIBILITY; BRACHIAL ARTERY; CONTROLLED STUDY; CORONARY STENT; DRUG TARGETING; ENZYME IMMOBILIZATION; EXPERIMENTAL PIG; FEMALE; FIBRINOLYTIC THERAPY; HEMOLYSIS; HUMAN; HUMAN CELL; HYSTERESIS; IN VITRO STUDY; IN VIVO STUDY; MATERIAL COATING; NONHUMAN; ONE POT SYNTHESIS; OXIDATION; PARTICLE SIZE; PRECIPITATION; PRIORITY JOURNAL; STENT THROMBOSIS;

ANIMALS; DRUG DELIVERY SYSTEMS; ENZYMES, IMMOBILIZED; ERYTHROCYTES; FEMALE; HEMOLYSIS; HUMANS; IMPLANTS, EXPERIMENTAL; MAGNETICS; MAGNETITE NANOPARTICLES; MATERIALS TESTING; RATS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE PROPERTIES; SUS SCROFA; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

RATTUS; SUIDAE;

EID: 78149414882     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.07.107     Document Type: Article

References (65)

1. Riehemann K., Schneider S.W., Luger T.A., Godin B., Ferrari M., Fuchs H. Nanomedicine - challenge and perspectives. Angew Chem Int Ed 2009, 48(5):872-897.
2. Doshi N., Mitragotri S. Designer biomaterials for nanomedicine. Adv Funct Mater 2009, 19(24):3843-3854.
3. McCarthy J.R., Weissleder R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev 2008, 60(11):1241-1251.
4. Laurent S., Forge D., Port M., Roch A., Robic C., Vander Elst L., et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev 2008, 108(6):2064-2110.
5. Gupta A.K., Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005, 26(18):3995-4021.
6. Widder K.J., Senyei A.E. Scarpelli DG Magnetic microspheres: a model system for site specfic drug delivery in vivo. Proc Soc Exp Biol Med 1978, 158(2):141-146.
7. Mosbach K., Schroder U. Preparation and application of magnetic polymers for targeting of drugs. FEBS Lett 1979, 102(1):112-116.
8. Alexiou C., Jurgons R., Schmid R., Hilpert A., Bergemann C., Parak F., et al. In vitro and in vivo investigations of targeted chemotherapy with magnetic nanoparticles. J Magn Magn Mater 2005, 293(1):389-393.
9. Lübbe A.S., Bergemann C., Riess H., Schriever F., Reichardt P., Possinger K., et al. Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res 1996, 56(20):4686-4693.
10. Li X.-S., Li W.-Q., Wang W.-B. Using targeted magnetic arsenic trioxide nanoparticles for osteosarcoma treatment. Cancer Biother Radiopharm 2007, 22(6):772-778.
11. Ma H.-L., Qi X.-R., Ding W.-X., Maitani Y., Nagai T. Magnetic targeting after femoral artery administration and biocompatibility assessment of superparamagnetic iron oxide nanoparticles. J Biomed Mater Res A 2008, 84(3):598-606.
12. Ma Y.-H., Wu S.-Y., Wu T., Chang Y.-J., Hua M.-Y., Chen J.-P. Magnetically targeted thrombolysis with recombinant tissue plasminogen activator bound to polyacrylic acid-coated nanoparticles. Biomaterials 2009, 30(19):3343-3351.
13. Chertok B., David A.E., Moffat B.A., Yang V.C. Substantiating in vivo magnetic brain tumor targeting of cationic iron oxide nanocarriers via adsorptive surface masking. Biomaterials 2009, 30(35):6780-6787.
14. Cherry E.M., Maxim P.G., Eaton J.K. Particle size, magnetic field, and blood velocity effects on particle retention in magnetic drug targeting. Med Phys 2010, 37(1):175-182.
15. Takeda S., Mishima F., Fujimoto S., Izumi Y., Nishijima S. Development of magnetically targeted drug delivery system using superconducting magnet. J Magn Magn Mater 2007, 311(1):367-371.
16. Terada T., Fukui S., Mishima F., Akiyama Y., Izumi Y., Nishijima S. Development of magnetic drug delivery system using HTS bulk magnet. Physica C 2008, 468(15-20):2133-2136.
17. Hirota Y., Akiyama Y., Izumi Y., Nishijima S. Fundamental study for development magnetic drug delivery system. Physica C 2009, 469(15-20):1853-1856.
18. Yellen B.B., Forbes Z.G., Halverson D.S., Fridman G., Barbee K.A., Chorny M., et al. Targeted drug delivery to magnetic implants for therapeutic applications. J Magn Magn Mater 2005, 293(1):647-654.
19. Rosengart A.J., Kaminski M.D., Chen H., Caviness P.L., Ebner A.D., Ritter J.A. Magnetizable implants and functionalized magnetic carriers: a novel approach for noninvasive yet targeted drug delivery. J Magn Magn Mater 2005, 293(1):633-638.
20. Fernández-Pacheco R., Valdivia J.G., Ibarra M.R. Magnetic nanoparticles for local drug delivery using magnetic implants. Methods Mol Biol 2009, 544(4):559-569.
21. Watson J.H.P. Status of superconducting magnetic separation in the minerals industry. Miner Eng 1994, 7(5-6):737-746.
22. Avilés M.O., Ebner A.D., Ritter J.A. Ferromagnetic seeding for the magnetic targeting of drugs and radiation in capillary beds. J Magn Magn Mater 2007, 310(1):131-144.
23. Avilés M.O., Ebner A.D., Ritter J.A. In vitro study of magnetic particle seeding for implant assisted-magnetic drug targeting. J Magn Magn Mater 2008, 320(21):2640-2646.
24. Avilés M.O., Ebner A.D., Ritter J.A. In vitro study of magnetic particle seeding for implant-assisted-magnetic drug targeting: seed and magnetic drug carrier particle capture. J Magn Magn Mater 2009, 321(10):1586-1590.
25. Ritter J.A., Ebner A.D., Daniel K.D., Stewart K.L. Application of high gradient magnetic separation principles to magnetic drug targeting. J Magn Magn Mater 2004, 280(2-3):184-201.
26. Chen H., Ebner A.D., Rosengart A.J., Kaminski M.D., Ritter J.A. Analysis of magnetic drug carrier particle capture by a magnetizable intravascular stent: 1. Parametric study with single wire correlation. J Magn Magn Mater 2004, 284(0):181-194.
27. Chen A., Ebner A.D., Kaminski M.D., Rosengart A.J., Ritter J.A. Analysis of magnetic drug carrier particle capture by a magnetizable intravascular stent-2: parametric study with multi-wire two-dimensional model. J Magn Magn Mater 2005, 293(1):616-632.
28. Avilés M.O., Chen H., Ebner A.D., Rosengart A.J., Kaminski M.D., Ritter J.A. In vitro study of ferromagnetic stents for implant assisted-magnetic drug targeting. J Magn Magn Mater 2007, 311(1):306-311.
29. Avilés M.O., Ebner A.D., Ritter J.A. Implant assisted-magnetic drug targeting: comparison of in vitro experiments with theory. J Magn Magn Mater 2008, 320(21):2704-2713.
30. Cregg P.J., Murphy K., Mardinoglu A. Calculation of nanoparticle capture efficiency in magnetic drug targeting. J Magn Magn Mater 2008, 320(23):3272-3275.
31. Cregg P.J., Murphy K., Mardinoglu A. Inclusion of magnetic dipole-dipole and hydrodynamic interactions in implant-assisted magnetic drug targeting. J Magn Magn Mater 2009, 321(23):3893-3898.
32. Avilés M.O., Mangual J.O., Ebner A.D., Ritter J.A. Isolated swine heart ventricle perfusion model for implant assisted-magnetic drug targeting. Int J Pharm 2008, 361(1-2):202-208.
33. Polyak B., Fishbein I., Chorny M., Alferiev I., Williams D., Yellen B., et al. High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents. Proc Natl Acad Sci USA 2008, 105(2):698-703.
34. Chorny M., Fishbein I., Yellen B.B., Alferiev I.S., Bakay M., Ganta S., et al. Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proc Natl Acad Sci USA 2010, 107(18):8346-8351.
35. Stähli B.E., Camici G.G., Tanner F.C. Drug-eluting stent thrombosis. Ther Adv Cardiovasc Dis 2009, 3(1):45-52.
36. Sugimoto T., Matijevic E. Formation of uniform spherical magnetite particles by crystallization from ferrous hydroxide gels. J Colloid Interface Sci 1980, 74(1):227-243.
37. Domingo C., Rodríguez-Clemente R., Blesa M.A. Kinetics of oxidative precipitation of iron oxide particles. Colloid Surf A 1993, 79(2-3):177-189.
38. Yu W.-G., Zhang T.-L., Qiao X.-J., Zhang J.-G., Yang L. Effects of synthetical conditions on octahedral magnetite nanoparticles. Mater Sci Eng B 2007, 136(2-3):101-105.
39. 2. J Phys Chem C 2008, 112(15):5843-5849.
40. Kaiser E., Colescott R.L., Bossinger C.D., Cook P.I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem 1970, 34(2):595-598.
41. Stewart J.M., Young J.D. Solid phase peptide synthesis 1984, Pierce, Rockford. 2nd ed.
42. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye-binding. Anal Biochem 1976, 72(1-2):248-254.
43. Nilsson K., Mosbach K. Tresyl chloride-activated supports for enzyme immobilization. Meth Enzymol 1987, 135:65-78.
44. Sasikumar P.G., Kempe M. Magnetic CLEAR supports for solid-phase synthesis of peptides and small organic molecules. Int J Pept Res Ther 2007, 13(1-2):129-141.
45. Götberg M., Olivecrona G., Engblom H., Ugander M., van der Pals J., Heiberg E., et al. Rapid short-duration hypothermia with cold saline and endovascular cooling before reperfusion reduces microvascular obstruction and myocardial infarct size. BMC Cardiovasc Disord 2008, 8:7.
46. Ma M., Zhang Y., Yu W., Shen H., Zhang H., Gu N. Preparation and characterization of magnetite nanoparticles coated by amino silane. Colloids Surf A 2003, 212(2-3):219-226.
47. Yamaura M., Camilo R.L., Sampaio L.C., Macêdo M.A., Nakamura M., Toma H.E. Preparation and characterization of (3-aminopropyl) triethoxysilane-coated magnetite nanoparticles. J Magn Magn Mater 2004, 279(2-3):210-217.
48. Stöber W., Fink A., Bohn E. Controlled growth of monodispersed silica spheres in the micron size range. J Colloid Interface Sci 1968, 26(1):62-69.
49. 3 precursors. J Mol Struct 2009, 919(1-3):140-145.
50. Mayer M. Biochemical and biological aspects of the plasminogen activation system. Clin Biochem 1990, 23(3):197-211.
51. Nieuwenhuizen W. Sites in fibrin involved in the acceleration of plasminogen activation by t-PA. Possible role of fibrin polymerization. Thromb Res 1994, 75(3):343-347.
52. Srere P., Uyeda K. Functional groups on enzymes suitable for binding to matrices. Meth Enzymol 1976, 44:169-183.
53. Scouten W.H. A survey of enzyme coupling techniques. Meth Enzymol 1987, 135:30-65.
54. Cao L. Immobilised enzymes: science or art?. Curr Opin Chem Biol 2005, 9(2):217-226.
55. Mateo C., Palomo J.M., Fernandez-Lorente G., Guisan J.M., Fernandez-Lafuente R. Improvement of enzyme activity, stability and selectivity via immobilization techniques. Enzyme Microb Technol 2007, 40(6):1451-1463.
56. Krimm S., Bandekar J. Vibrational spectroscopy and conformation of peptides, polypeptides, and proteins. Adv Protein Chem 1986, 38:181-364.
57. Kong J., Yu S. Fourier transform infrared spectroscopic analysis of protein secondary structures. Acta Biochim Biophys Sin 2007, 39(8):549-559.
58. Nash T., Allison A.C., Harington J.S. Physico-chemical properties of silica in relation to its toxicity. Nature 1966, 210(5033):259-261.
59. Razzaboni B.L., Bolsaitis P. Evidence of an oxidative mechanism for the hemolytic activity of silica particles. Environ Health Persp 1990, 87:337-341.
60. Murashov V., Harper M., Demchuk E. Impact of silanol surface density on the toxicity of silica aerosols measured by erythrocyte haemolysis. J Occup Environ Hyg 2006, 3(12):718-723.
61. Hadnagy W., Marsetz B., Idel H. Hemolytic activity of crystalline silica - separated erythrocytes versus whole blood. Int J Hyg Environ Health 2003, 206(2):103-107.
62. Owens D.E., Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006, 307(1):93-102.
63. Yu W., Zhang T., Zhang J., Qiao X., Yang L., Liu Y. The synthesis of octahedral nanoparticles of magnetite. Mater Lett 2006, 60(24):2998-3001.
64. Decuzzi P., Ferrari M. The adhesive strength of non-spherical particles mediated by specific interactions. Biomaterials 2006, 27(30):5307-5314.
65. Smalling R.W. Role of fibrinolytic therapy in the current era of ST-segment elevation myocardial infarction management. Am Heart J 2006, 151(6):S17-S23.